Trabectedin as a chemotherapy option for patients with BRCA deficiency

Bradley J. Monk, Domenica Lorusso, Antoine Italiano, Stan B. Kaye, Miguel Aracil, Adnan Tanović, Maurizio D'Incalci

Research output: Contribution to journalReview article

Abstract

Trabectedin is a marine-derived product that was originally isolated from the Caribbean sea squirt Ecteinascidia turbinata and the first anticancer marine drug to be approved by the European Union. It is currently used as a single agent for the treatment of patients with soft tissue sarcoma after failure of anthracyclines and ifosfamide, or for those patients who are unsuited to receive these agents, and in patients with relapsed, platinum-sensitive ovarian cancer in combination with pegylated liposomal doxorubicin. Trabectedin has a unique multi-faceted mechanism of action that involves transcription regulation and DNA repair systems, including transcription-coupled nucleotide excision repair and homologous recombination repair (HRR) as the main hallmarks of its antiproliferative activity. In addition, trabectedin has shown the ability to modulate the tumor microenvironment. Indeed, the activity of trabectedin is related to altered function and expression of DNA repair genes, such as BRCA1 (BReast-CAncer susceptibility gene 1) and BRCA2. The particular sensitivity of sarcoma, ovarian and breast cancer cells deficient in HRR, previously observed in preclinical models, now has been confirmed in the clinical setting as well, suggesting that BRCA mutations are associated with improved clinical responses to trabectedin. Current efforts are focused on the evaluation of these unique features of trabectedin and on the identification of predictive factors for patients with an objective to determine whether a deficiency of HRR DNA repair pathway could impact the clinical benefit achieved from trabectedin.

Original languageEnglish
Pages (from-to)175-182
Number of pages8
JournalCancer Treatment Reviews
Volume50
DOIs
Publication statusPublished - Nov 1 2016

Keywords

  • BRCA
  • Breast
  • Mutations
  • Ovarian cancer
  • Sarcoma
  • Trabectedin
  • Yondelis®

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Trabectedin as a chemotherapy option for patients with BRCA deficiency'. Together they form a unique fingerprint.

  • Cite this

    Monk, B. J., Lorusso, D., Italiano, A., Kaye, S. B., Aracil, M., Tanović, A., & D'Incalci, M. (2016). Trabectedin as a chemotherapy option for patients with BRCA deficiency. Cancer Treatment Reviews, 50, 175-182. https://doi.org/10.1016/j.ctrv.2016.09.009